# Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT07090369** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 20 (estimated)

## Conditions studied

- Metastatic Castrate Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Olaparib (300 mg BID)
- **DRUG:** Pembrolizumab
- **RADIATION:** 177Lu-PSMA-I&T

## Key facts

- **NCT ID:** NCT07090369
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090369, "Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07090369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*